Chronic lymphocytic leukaemia (CLL) is characterized by relapse after treatment and chemotherapy resistance. Like in other malignancies, leukaemia cells accumulate mutations during growth, forming heterogeneous cell populations that are subject to Darwinian selection and may respond differentially to treatment. There is therefore a clinical need to monitor changes in the subclonal composition of cancers during disease progression.
Introduction
Despite significant progress in the management of lymphomas and leukaemias, relapse remains the major cause of death. Increased use of expensive targeted therapies and toxic chemotherapies (especially in the elderly) confronts us with an urgent need to improve response prediction for all cancer patients in order to reduce side-effects and costs from ineffective treatment. Current diagnostic approaches to treatment selection, response monitoring and relapse prediction are limited to single genes and apply only to a minority of haematological cancers. This is at odds with modern concepts of tumour propagation and maintenance, which propose that every cell in an individual cancer is characterised by a combination of mutation events that comprise tumorigenic (driver) mutations, passive (passenger) mutations, and possibly predisposing germline risk variants. Cancer cells propagate and diversify during tumour growth, resulting in a heterogeneous population of genotypically and phenotypically distinct subclones that are related in a hierarchical lineage. As the composition of the local environment changes, for example as a consequence of drug treatment, tumour cell populations adapt and evolve by Darwinian selection [1] [2] [3] . Whole genome sequencing (WGS) of a single tumour sample can be used to generate a comprehensive catalogue of variants that provides a snapshot of the cell population en masse at a particular time-point 2,4-6 . However, over time and with continued evolution of the cancer, this snapshot becomes progressively less representative of the disease. Recent reports have described whole tumour genomes from single patients or cohorts of individuals mostly at single time-points and irrespective of treatment [7] [8] [9] [10] . This approach has enabled identification of mutations representative and in some cases highly predictive of histological cancer type, outcome and/or treatment response [11] [12] [13] [14] [15] . Comparison of sequence data from primary and metastatic tumour samples, or from multiple locations within a tumour, reveals major differences in the somatic mutation profiles within an individual, illustrating the dynamic nature of tumour evolution [16] [17] [18] . Recently, two time-point analysis of relapsed 19 and secondary 20 acute myeloid leukaemia have also demonstrated clonal evolution at a molecular level.
We elected to study subclonal evolution in B-cell chronic lymphocytic leukaemia (CLL). CLL is characterised by immunodeficiency, autoimmunity, a chronically relapsing course and the development of chemotherapy resistance, making it an ideal model to study tumour progression. Using WGS analysis, we tracked molecular changes in pre-treatment, post-treatment and relapse samples in three patients. We defined cellular subpopulations on the basis of somatic mutation profiles and revealed changes within the tumour clonal architecture over time as patients were subjected to multiple rounds of treatment. We describe for the first time the heterogeneous patterns of clonal evolution in patients with IgHV unmutated CLL throughout the lifetime of their disease. This proof-of-principle study enabled us to evaluate how large-scale sequence information might be used in future clinical trials to evaluate response and to target therapies more effectively for patients suffering from CLL and perhaps other cancers. 
Mutation frequency profiles differ between patients and change over time
We determined allele frequencies of all somatic single nucleotide variants (SNVs) at each disease stage, established a profile for each mutation during disease progression and grouped similar mutation profiles together. This revealed changes in mutation profiles over time and clear differences between patients (Fig. 1a-c) . The most dynamic profiles were seen in CLL003. Mutation profiles of CLL077 were relatively stable initially and then underwent a change at later stages. Finally, CLL006 mutation profiles remained relatively stable throughout.
To extend the sensitivity of the study we selected specific somatic mutations from each profile, focusing on those predicted to alter protein structure. We performed targeted deep sequencing to an average depth of 100000x to quantify the mutation frequency at each stage to high accuracy and to observe low levels of somatic mutations (down to ~0.5%) previously undetected by WGS (Fig. 1d , Supplementary   Fig. 3 and Supplementary Tables 5-7). All mutations selected were confirmed by deep sequencing (see Methods). The quantitative analysis revealed a striking similarity in frequency profiles for different mutations in the same group ( Fig. 1d and Supplementary Fig. 3 ). Considering the deep sequence and WGS data we defined five mutation profiles: (1) high (H) frequency at initial diagnosis and later (HH); (2) high at diagnosis then low (L) or disappearing after treatment (HL); (3) initially at low frequency but then increasing (LH); (4) undetectable by deep sequencing at diagnosis (0H); (5) present at low frequency throughout (LL). All five profiles are evident in CLL003, but only HH, 0H and LL profiles are present in CLL077, while CLL006 is characterised exclusively by HH and LL profiles (Fig. 1, Supplementary   Fig. 3 ).
Defining leukaemia architecture and founder mutations
We used the deep sequencing data to define tumour subclones and to infer an evolving and branching cellular hierarchy of tumour cells for the three patients (Fig.   2 ). This analysis enabled us to define a founder subclone in each patient that was genetically characterized by mutations present in all tumour cells at all time points (mutation profile HH F in Fig. 1d , Fig. 2 and Supplementary Fig.3 ). Mutations of this type should include the initial drivers of tumourigenesis, as well as passenger mutations that were fixed in the originating tumour cell. Additional subclone diversity was due to other mutations (HL, LH, 0H, HH profiles in Fig. 1d , Fig. 2 and Supplementary Fig. 3 ) that arose on the background of the founder mutations.
The list of mutated genes was unique to each patient (Supplementary Tables 6-8) .
However, each carried one or more candidate driver mutations based on recurrence in CLL [25] [26] [27] [28] [29] [30] or other cancers 31 (Supplementary Table 10 ). Importantly, a single somatic founder mutation in each patient affected a gene recurrently mutated in CLL (CLL003: SF3B1; CLL077: SAMHD1; CLL006: MED12). A further 5-10 non-recurrent mutations were fixed within the founder clone and could include both driver and passenger events. By contrast, ATM, PLEKHG5 and IRF4 mutations, although recurrent in CLL, were clearly secondary events, as they were not observed in all tumour cells and because their allele frequency reduced during treatment. We showed that phosphorylated ERK1/2 increased over time in lymphocytes of patient CLL077 and that this mirrored the expansion of the subclone containing the mutation (Supplementary Figure 6 ). Although this does not prove the pathogenic mechanism, it implies that the mutated MAP2K1 gene product was active in this patient at these time-points. At relapse before death subclone 4 was pre-dominant in 
Discussion
Cancers initiate from a single cell with one or more founder mutations and acquire additional mutations, some of which may give rise to resistance or confer sensitivity to treatment. We demonstrate that WGS provides an abundance of mutated sites whose allele frequency profiles can be grouped to reveal the likely evolving subclonal hierarchy of leukaemia. Additionally, WGS provides information on somatic mutations in non-coding regions, whose significance for cancer currently remains to be determined.
In all three patients, we identified founder events that could be future targets for curative therapy in CLL. Further, in all patients WGS defined the genetic composition of subclones that later became dominant even before initiation of relapse treatment.
In some cases these changes to the molecular phenotype of the tumour became apparent months or years ahead of an obvious clinical phenotype, thus offering the possibility for earlier targeted and sequential treatment selection directed against these subclones, which are characterized by the presence of non-recurrent or lowrecurrence mutations. In practice however, this approach might only shift the balance of the different subclones but not affect the ultimate outcome for the patient.
We show that genome-wide tracking of somatic mutation profiles over time reveals heterogeneous patterns of clonal evolution in CLL. All three patients had multiple and is more similar to the pattern observed in MDS/AML progression 20 . Relapse in two of the CLL patients is also characterized by emergence and expansion of subclones that were not present at diagnosis.
We identify both dynamic/rapid and stable/gradual shifts in the interclonal balance.
The clinical and prognostic significance of these subclonal shifts remains to be established. For example, we have seen that a relatively stable molecular phenotype in patient CLL006 correlates with slow disease progression and a good response to repeated treatment, whereas emerging or increasing subclones in the other two patients correlate with resistance to different treatments and death. It could be that in patients CLL003 and CLL077 the chemotherapy itself selected for chemo-resistant subclones and/or induced new mutations causing resistance through DNA damage.
These conferred a survival advantage and led to expansion of resistant subclones.
By contrast, this did not occur in CLL006 who was treated almost exclusively with antibodies. Going forward, the potential clinical utility of our analysis approach will need to be evaluated systematically within clinical trials in larger cohorts of patients.
Depending on the outcome of these studies, longitudinal WGS studies may eventually provide a means to individualise treatment 38 .
Challenges remain to genome-wide sequencing being applied within clinical trials.
These include simplifying and standardising the currently complex analysis methods, and improving turnaround time, costs and interpretation of clinically actionable information. Clinical implementation also depends on the availability of sequential biopsies, access to integrated phenotype-genotype databases and effective therapeutics.
Given progress in all these areas, we anticipate that genome-wide sequencing will become an effective approach to monitor disease progression systematically and also prospectively, and that it will direct future clinical trials and therapeutic decisions.
Its successful implementation could fundamentally change our strategy for treatment selection and monitoring and provide the tool for delivering more successful and cost-effective healthcare with better outcomes for individual patients.
For
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